Myocardial infarction is death of cardiac myocytes (necrosis) caused by prolonged ischemia. The term acute "usually" refers to the time 6 hours to 7 days following pathologic appearance of the infarct.
The patient may experience ischemic-type chest discomfort with accompanying symptoms of nausea, vomiting, dyspnea, diaphoresis, lightheadedness, dizziness, syncope, fatigue and weakness.
Rapid diagnosis and risk stratification of chest pain in patients are important to identify acute myocardial infarction patients who will benefit from reperfusion therapy.
A new risk model for predicting 6-month mortality for older adults hospitalized with acute myocardial infarction (AMI) has been developed, demonstrating good calibration and discrimination, reports a recent study.
The use of a genotype-guided strategy for selection of oral P2Y12 inhibitor therapy appears to benefit patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI), such that noncarriers of CYP2C19 loss-of-function alleles have favourable bleeding outcomes with clopidogrel vs standard treatment with ticagrelor or prasugrel, according to data from the POPular Genetics* trial.
A single testing of cardiac troponin I using a high-sensitivity assay can effectively rule out myocardial infarction (MI) without compromising safety, according to the HiSTORIC* study presented at the ESC 2019 Congress.
People with sleep duration shorter than 6 hours/night have an increased risk of myocardial infarction (MI) than those who slept 6–9 hours/night, with additional data from Mendelian randomization supporting a causal link between sleep duration and MI, a new study has shown.
Complete revascularization has been shown to be superior to culprit-lesion-only percutaneous coronary intervention (PCI) in reducing major cardiovascular (CV) events, according to results of the COMPLETE trial reported at the European Society of Cardiology (ESC) Congress 2019 and World Congress of Cardiology (WCC) 2019.
More intensive LDL-lowering by adding ezetimibe to simvastatin in elderly individuals aged ≥75 years significantly reduced recurrent cardiovascular (CV) events without raising safety issues compared with simvastatin alone, a secondary analysis of the IMPROVE-IT* has shown.
The absence of the classical symptom of chest pain in patients with acute myocardial infarction (AMI) appears to be associated with more complications and higher short- and long-term mortality rates, particularly in younger and healthier patients, according to a study.
Young individuals with high blood pressure (BP) are more likely to experience a recurrent heart attack than those without hypertension, according to a study presented at the ACC Asia Conference 2018 in Shanghai, China, highlighting that secondary preventive programmes should target modifiable risk factors for younger patients.
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.